VRDN Viridian Therapeutics, Inc. Stock Quote

VRDN [NASD]

Index	-	P/E	-	EPS (ttm)	-5.76	Insider Own	1.70%	Shs Outstand	26.13M	Perf Week	-2.46%
Market Cap	318.97M	Forward P/E	-	EPS next Y	-3.37	Insider Trans	-22.84%	Shs Float	18.72M	Perf Month	-11.86%
Income	-86.60M	PEG	-	EPS next Q	-0.90	Inst Own	91.70%	Short Float	7.98%	Perf Quarter	-42.13%
Sales	1.70M	P/S	187.63	EPS this Y	78.60%	Inst Trans	6.98%	Short Ratio	4.59	Perf Half Y	-47.29%
Book/sh	2.09	P/B	5.12	EPS next Y	10.20%	ROA	-47.70%	Target Price	33.11	Perf Year	-40.22%
Cash/sh	5.89	P/C	1.82	EPS next 5Y	-	ROE	-360.70%	52W Range	9.47 - 22.00	Perf YTD	-45.88%
Dividend	-	P/FCF	-	EPS past 5Y	56.40%	ROI	-147.90%	52W High	-51.36%	Beta	1.14
Dividend %	-	Quick Ratio	12.50	Sales past 5Y	-3.10%	Gross Margin	-	52W Low	12.99%	ATR	0.98
Employees	50	Current Ratio	12.50	Sales Q/Q	-86.70%	Oper. Margin	-	RSI (14)	43.23	Volatility	9.96% 9.21%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	66.20%	Profit Margin	-	Rel Volume	0.52	Prev Close	11.57
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 12 AMC	Payout	-	Avg Volume	325.36K	Price	10.70
Recom	1.40	SMA20	-4.58%	SMA50	-12.77%	SMA200	-36.81%	Volume	168,141	Change	-7.52%

Jun-23-22

Initiated

B. Riley Securities

Buy

$25

Nov-18-21

Initiated

SVB Leerink

Outperform

$32

Oct-12-21

Initiated

Evercore ISI

Outperform

$40

Jan-25-21

Initiated

Ladenburg Thalmann

Buy

$40

Jun-23-22 07:00AM	Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer GlobeNewswire +6.36%
Jun-03-22 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.69%
Jun-01-22 08:00AM	Viridian Therapeutics to Participate in June Investor Conferences GlobeNewswire
May-12-22 04:05PM	Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates GlobeNewswire +5.49%
May-03-22 08:00AM	Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022 GlobeNewswire
Apr-06-22 08:00AM	Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14 GlobeNewswire
Apr-04-22 04:05PM	Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital GlobeNewswire
Mar-21-22 04:05PM	Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease GlobeNewswire
Mar-14-22 06:36PM	Oppenheimer Bets on These 2 Stocks; Sees Over 40% Upside Potential TipRanks
04:05PM	Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15 GlobeNewswire
Mar-10-22 04:05PM	Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates GlobeNewswire
10:33AM	Strong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of five-year loss Simply Wall St.
Mar-03-22 04:16PM	Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022 GlobeNewswire
Feb-14-22 08:00AM	Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18 GlobeNewswire
Jan-31-22 07:00AM	Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease GlobeNewswire +9.66%
Jan-04-22 07:00AM	Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration GlobeNewswire
Dec-20-21 07:00AM	Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED) GlobeNewswire
Nov-30-21 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.07%
Nov-15-21 07:00AM	Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED) GlobeNewswire
Nov-04-21 04:05PM	Viridian Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Updates GlobeNewswire
Nov-03-21 04:05PM	Viridian Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Oct-14-21 08:00AM	Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration GlobeNewswire
Sep-30-21 08:06AM	Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association GlobeNewswire
Sep-23-21 04:01PM	Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares GlobeNewswire
Sep-21-21 12:22AM	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock GlobeNewswire +17.96%
Sep-20-21 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock GlobeNewswire -8.08%
Aug-23-21 02:36PM	Strong week for Viridian Therapeutics (NASDAQ:VRDN) shareholders doesn't alleviate pain of three-year loss Simply Wall St.
Aug-11-21 07:00AM	Viridian Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Updates GlobeNewswire -13.93%
Aug-05-21 08:30AM	Viridian Therapeutics to Participate in the Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire +5.52%
Jul-26-21 07:30AM	Viridian Therapeutics Appoints Kristian Humer as Chief Financial Officer and Chief Business Officer GlobeNewswire
Jul-15-21 04:05PM	Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee GlobeNewswire
Jul-14-21 08:00AM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jul-07-21 08:00AM	Viridian Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference GlobeNewswire
Jun-10-21 08:00AM	Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference GlobeNewswire
May-24-21 10:45AM	How Many Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Do Institutions Own? Simply Wall St.
May-14-21 08:00AM	Viridian Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
May-06-21 04:05PM	Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates GlobeNewswire -5.29%
Mar-25-21 04:05PM	Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates GlobeNewswire
02:30PM	Viridian Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-23-21 04:00AM	Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies GlobeNewswire
Mar-09-21 04:30PM	Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update GlobeNewswire +7.67%
Feb-22-21 08:00AM	Viridian Therapeutics to Present at Three Upcoming Investor Conferences GlobeNewswire
07:45AM	Reflecting on Viridian Therapeutics' (NASDAQ:VRDN) Share Price Returns Over The Last Three Years Simply Wall St.

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Violin Jonathan	Chief Executive Officer	Jun 01	Sale	12.20	30,000	366,000	480,905	Jun 02 05:29 PM
Violin Jonathan	Chief Executive Officer	May 02	Sale	13.04	30,000	391,200	510,905	May 04 05:23 PM
Violin Jonathan	Chief Executive Officer	Apr 04	Sale	18.93	3,600	68,148	540,905	Apr 05 06:09 PM
Violin Jonathan	Chief Executive Officer	Apr 01	Sale	18.92	26,400	499,488	544,505	Apr 05 06:09 PM
Violin Jonathan	Chief Executive Officer	Mar 02	Sale	17.36	11,106	192,800	570,905	Mar 03 04:48 PM
Violin Jonathan	Chief Executive Officer	Mar 01	Sale	17.82	18,894	336,691	582,011	Mar 03 04:48 PM
Violin Jonathan	Chief Executive Officer	Feb 03	Sale	19.16	909	17,416	600,905	Feb 03 06:11 PM
Violin Jonathan	Chief Executive Officer	Feb 02	Sale	18.47	12,340	227,920	601,814	Feb 03 06:11 PM
Violin Jonathan	Chief Executive Officer	Feb 01	Sale	19.55	16,751	327,482	614,154	Feb 03 06:11 PM
Frazier Life Sciences Public F	10% Owner	Sep 23	Buy	11.00	200,000	2,200,000	1,505,200	Sep 28 07:46 PM
Fairmount Funds Management LLC	Director	Sep 21	Buy	11.00	909,000	9,999,000	938,233	Sep 23 09:30 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience